This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant Neoplasm of Retroperitoneum and Peritoneum후복막 및 복막의 악성신생물 (후복막암)

Classification codesC48 (ICD-10) — C48.0 retroperitoneum, C48.1 specified parts of peritoneum, C48.2 peritoneum, unspecified, C48.8 overlapping lesion
SynonymsRetroperitoneal sarcoma, Peritoneal mesothelioma, Peritoneal carcinomatosis, primary peritoneal cancer, Pseudomyxoma peritonei
Adult onsetNot low — occurs mainly in middle-aged and older adults (40s–70s); peritoneal mesothelioma shows male predominance in the 50s–70s
Special Copayment ReductionV193 — 5 years from the date of cancer patient registration, copayment 5%
1. HistoryHistory of retroperitoneal sarcoma classification; link between peritoneal mesothelioma and asbestos (1960s); introduction of HIPEC
2. CausesAsbestos (peritoneal mesothelioma), radiation, genetic predisposition (NF1, Li-Fraumeni), intraperitoneal spread
3. GeneticsMDM2/CDK4 amplification (liposarcoma), NF2/BAP1/CDKN2A (mesothelioma), TP53/RB1 (sarcoma)
4. EpidemiologyKorea: 757 cases in 2010 → 1,642 cases in 2023; 67.7% malignant, sarcoma the most common type
5. PathophysiologyMalignant transformation of mesenchymal cells; mesothelial cell DNA damage by asbestos fibers; intraperitoneal dissemination
6. SymptomsAbdominal discomfort and distension, abdominal mass, weight loss; ascites in peritoneal mesothelioma
7. SignsAbdominal mass, ascites, lower limb edema; symptoms of retroperitoneal nerve and vessel compression
8. ScreeningNo screening for the general population; CT/MRI follow-up for high-risk groups (asbestos exposure, Li-Fraumeni)
9. DiagnosisCT/MRI/PET-CT/laparoscopic biopsy/IHC/molecular testing; laparoscopic exploration for peritoneal cancer
10. TreatmentCytoreductive surgery (CRS) + HIPEC; wide retroperitoneal resection; doxorubicin; pemetrexed (mesothelioma)
11. PrognosisRetroperitoneal sarcoma 5-year survival 40–60%; peritoneal mesothelioma median survival 52 months (CRS + HIPEC)
12. PreventionBan on asbestos exposure, management of occupational carcinogens, genetic counseling, follow-up of high-risk groups
13. ReferencesKey references

1. History

Malignant neoplasms of the retroperitoneum and peritoneum include an anatomically broad range of tumor types, each with its own independent historical development. The history of Retroperitoneal sarcoma (RPS) began with the development of pathology in the mid-19th century. Initially these tumors were simply classified as intra-abdominal tumors, but with advances in soft tissue pathology in the early 20th century they were subdivided into liposarcoma, leiomyosarcoma, undifferentiated pleomorphic sarcoma and others. In particular, the introduction of CT in the 1970s–1980s made it possible to determine the location and extent of the tumor accurately before surgery, bringing a revolutionary change to surgical strategy for retroperitoneal sarcoma.

Peritoneal mesothelioma began to attract attention in the 1960s, when its association with asbestos exposure was confirmed. After Wagner et al. first reported the association between pleural mesothelioma and asbestos in 1960, peritoneal mesothelioma was shown to share the same carcinogenic mechanism. In Korea, asbestos use increased during industrialization, and the subsequent rise in asbestos-related diseases emerged as a social problem. In Korea, the Asbestos Safety Management Act was enacted in 2009 and the use of asbestos was completely banned.

Pseudomyxoma peritonei (PMP) was first described by Carl von Rokitansky in 1842 and was found to originate mainly from mucinous tumors of the appendix. The most groundbreaking development in its treatment was cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), introduced by Paul Sugarbaker in the 1990s. The introduction of HIPEC greatly improved the prognosis of peritoneal surface malignancies, and it is now recognized as standard treatment at major institutions worldwide. In Korea, a specialized HIPEC clinic operates centered at Ajou University Hospital, and a retroperitoneal tumor clinic opened in April 2023.

According to recent Korean statistics, the number of diagnoses of retroperitoneal malignant neoplasms (ICD-10 C480) more than doubled from 757 in 2010 to 1,642 in 2023, and in response, specialized multidisciplinary treatment systems are being built. ESMO (European Society for Medical Oncology) and NCCN guidelines strongly recommend treatment of retroperitoneal sarcoma at specialized centers.

2. Causes

The causes of malignant neoplasms of the retroperitoneum and peritoneum differ greatly by tumor type and should be understood separately for sarcoma, mesothelioma and peritoneal carcinomatosis.

Causes of retroperitoneal sarcoma

Causes of peritoneal mesothelioma

Asbestos exposure is the most important cause; a history of asbestos exposure is found in about 30–50% of patients with peritoneal mesothelioma. Crocidolite (blue asbestos) and amosite (brown asbestos) are known to be more carcinogenic than chrysotile (white asbestos). The latency is very long, at 20–50 years. Germline mutations of the BAP1 gene greatly increase the risk of mesothelioma, including peritoneal mesothelioma.

Peritoneal carcinomatosis (metastatic)

A considerable proportion of peritoneal malignancies are peritoneal carcinomatosis, in which primary cancers such as colorectal, gastric, ovarian and appendiceal cancer have metastasized into the peritoneal cavity. Pseudomyxoma peritonei originates mainly from mucinous adenocarcinoma of the appendix, with mucinous material disseminated throughout the peritoneal cavity.

3. Genetics

The genetics of malignant neoplasms of the retroperitoneum and peritoneum is highly heterogeneous depending on tumor type.

Retroperitoneal liposarcoma

Well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS), the most common type of retroperitoneal sarcoma, is characterized by amplification of the MDM2 and CDK4 genes on the long arm of chromosome 12 (12q13-15). MDM2 amplification suppresses p53 function, blocking tumor-suppressive mechanisms, and CDK4 amplification accelerates the G1-S cell-cycle transition. Immunohistochemistry and FISH for MDM2 and CDK4 are key to the diagnosis of liposarcoma. Myxoid liposarcoma is characterized by the FUS-DDIT3 (95%) or EWSR1-DDIT3 (5%) fusion gene.

Retroperitoneal leiomyosarcoma

In retroperitoneal leiomyosarcoma, mutations such as TP53, RB1, ATRX, PTEN and complex karyotypic abnormalities are observed. MDM2 amplification is generally absent, which is useful for differentiation from liposarcoma.

Peritoneal mesothelioma

In peritoneal mesothelioma, mutations in NF2 (22q12; about 40–50%), BAP1 (about 25%), CDKN2A (p16) (about 25–30%) and TP53 (about 10%) are common. Germline BAP1 mutations are associated with a hereditary syndrome (BAP1 tumor predisposition syndrome) that increases the risk of peritoneal mesothelioma, pleural mesothelioma, uveal melanoma, renal cell carcinoma and others. PD-L1 expression is observed in some mesotheliomas and is a target of immunotherapy (pemetrexed + platinum + nivolumab).

4. General epidemiology

Malignant neoplasms of the retroperitoneum and peritoneum are rare tumors accounting for about 0.1–0.5% of all malignancies, but the number of cases in Korea has recently been increasing. According to data from the Ajou University Hospital retroperitoneal tumor clinic, the annual number of diagnoses of retroperitoneal malignant neoplasms (ICD-10 C480) in Korea increased about 2.2-fold, from 757 in 2010 to 1,642 in 2023.

Retroperitoneal sarcoma accounts for about 15% of all soft tissue sarcomas, and the most common types are liposarcoma (41–45%) and leiomyosarcoma (28%). The median age at onset is in the 50s–60s, and sex differences vary by type. Peritoneal mesothelioma accounts for about 20–25% of all mesotheliomas and, unlike pleural mesothelioma, is relatively common in women as well. Pseudomyxoma peritonei (PMP) is a very rare disease at about 2 per million population, with female predominance (F:M ≈ 3:2). In Korea, the incidence of peritoneal mesothelioma is expected to decline gradually along with the reduction in occupational asbestos exposure.

5. Pathophysiology

The pathogenesis of malignant neoplasms of the retroperitoneum and peritoneum varies by tumor type.

Pathogenesis of retroperitoneal sarcoma

Retroperitoneal liposarcoma arises from retroperitoneal adipocytes or preadipocytes through genomic instability centered on MDM2/CDK4 amplification. MDM2 amplification blocks the p53 tumor-suppressor pathway and CDK4 amplification accelerates the cell cycle, leading to malignant transformation of adipocytes. Dedifferentiated liposarcoma (DDLPS) arises from well-differentiated liposarcoma (WDLPS) through the accumulation of additional genomic abnormalities (TERT amplification, TP53 mutation, etc.). Leiomyosarcoma arises from vascular smooth muscle cells or retroperitoneal smooth muscle, centered on loss of function of TP53, RB1 and others.

Pathogenesis of peritoneal mesothelioma

Asbestos fibers enter the peritoneal cavity and continuously stimulate mesothelial cells, inducing reactive oxygen species (ROS) production and DNA double-strand breaks. In this process, malignant transformation of mesothelial cells occurs as the function of tumor-suppressor genes such as NF2, BAP1, CDKN2A is lost. The latency is long, at 20–50 years, reflecting the time needed to accumulate multistep genetic events.

Pathogenesis of peritoneal carcinomatosis (disseminated metastasis)

Primary cancer cells invade the serosa, detach into the peritoneal cavity, and implant and proliferate on the peritoneal surface. This process involves epithelial–mesenchymal transition (EMT) due to loss of E-cadherin, activation of matrix metalloproteinases (MMPs) and angiogenesis.

6. Symptoms

Malignant neoplasms of the retroperitoneum and peritoneum are often asymptomatic or nonspecific in the early stage, so diagnosis tends to be delayed.

Symptoms of retroperitoneal tumors

Symptoms of peritoneal tumors

7. Signs

The main signs observed on physical examination are as follows.

Retroperitoneal tumors

Peritoneal tumors

8. Screening

No standard screening program for malignant neoplasms of the retroperitoneum and peritoneum has been established for the general population.

Monitoring of high-risk groups

9. Diagnosis

The diagnosis of malignant neoplasms of the retroperitoneum and peritoneum is made by imaging studies and histopathologic confirmation.

Imaging tests

Histopathological diagnosis

10. Treatment

Treatment of malignant neoplasms of the retroperitoneum and peritoneum differs greatly depending on tumor type and resectability.

Surgery for retroperitoneal sarcoma

Complete tumor resection (R0 resection) is the cornerstone of treatment. In retroperitoneal sarcoma, obtaining clear margins is difficult because of anatomic constraints, and multivisceral resection (MVR) is often needed. According to 2015–2024 data from the Ajou University Hospital retroperitoneal tumor clinic, there was a significant difference in survival between the MVR and non-MVR groups. At recurrence, repeat resection is actively considered and is performed at specialized centers experienced in re-resection.

Peritoneal surface malignancies: CRS + HIPEC

Cytoreductive surgery (CRS) and HIPEC is a treatment approach for selected peritoneal surface malignancies (pseudomyxoma peritonei, peritoneal mesothelioma, peritoneal metastasis of colorectal cancer, peritoneal metastasis of ovarian cancer, primary peritoneal sarcoma). HIPEC is a method of perfusing the peritoneal cavity for 60–90 minutes with anticancer drugs (cisplatin, mitomycin C, oxaliplatin, etc.) heated to 42–43°C. CRS + HIPEC has been reported to achieve a 10-year survival rate of 70–80% in pseudomyxoma peritonei and a median survival of 52 months in peritoneal mesothelioma.

Systemic therapy

11. Prognosis

Tumor typePrognosis
Overall 5-year survival rate of retroperitoneal sarcoma40–60% (improved with R0 resection; poor for the dedifferentiated type)
5-year survival rate of retroperitoneal liposarcoma (WDLPS)About 80–90% (frequent recurrence; 10-year survival about 55–65%)
5-year survival rate of retroperitoneal liposarcoma (DDLPS)About 40–50%
5-year survival rate of retroperitoneal leiomyosarcomaAbout 30–50%
Median survival of peritoneal mesothelioma after CRS + HIPECAbout 52 months
10-year survival rate of pseudomyxoma peritonei (PMP) after CRS + HIPEC70–80% (low-grade PMP)
5-year survival rate of peritoneal carcinomatosis (colorectal origin) after CRS + HIPECAbout 30–45% (selected patients)

Prognostic factors include histologic type and grade of the tumor, resectability (R0/R1/R2), recurrence, extent of peritoneal carcinomatosis (PCI) and distant metastasis. In retroperitoneal sarcoma, local recurrence is the main pattern of failure, with a mean time to recurrence of 2–3 years.

12. Prevention

Prevention of asbestos exposure

Genetic counseling and follow-up of high-risk groups

13. References

  1. Surgical outcomes and prognostic factors in retroperitoneal tumors: single-center retrospective cohort study (2015-2024). ASTR. 2026. DOI: 10.4174/astr.2026.110.2.119.
  2. Retroperitoneal sarcomas: Outcomes of repeated resections. Korean J Clin Oncol. PMC.
  3. Neoadjuvant Chemotherapy for Retroperitoneal Sarcoma: Systematic Review and Meta-Analysis. PMC12455522. 2025.
  4. Peritoneal Mesothelioma: Systematic Review of HIPEC Protocol Outcomes. PMC10284774. 2023.
  5. Correlation between PSOGI pathological classification and survival of PMP treated with CRS and HIPEC. PMC10249754. 2023.
  6. Surgical Experience with Retroperitoneal Liposarcoma in a Single Korean Tertiary Medical Center. PMC3364469.
  7. WHO Classification of Soft Tissue and Bone Tumours. 5th ed. IARC Press. 2020.
  8. National Cancer Information Center. Cancer statistics in Korea 2023. 2025.
  9. Asbestos Safety Management Act (Korea). 2009. Ministry of Environment.
  10. ESMO Clinical Practice Guidelines: Soft Tissue and Visceral Sarcomas. 2021.